- Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
- Lineage Announces Changes to Board of Directors
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
More ▼
Key statistics
On Saturday, Lineage Cell Therapeutics Inc (LCTX:ASQ) closed at 1.08, 28.36% above the 52 week low of 0.8414 set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.09 |
Low | 1.02 |
Bid | 1.06 |
Offer | 1.10 |
Previous close | 1.06 |
Average volume | 1.36m |
---|---|
Shares outstanding | 188.80m |
Free float | 187.99m |
P/E (TTM) | -- |
Market cap | 205.79m USD |
EPS (TTM) | -0.1344 USD |
Data delayed at least 15 minutes, as of May 18 2024.
More ▼